Published in Chest on October 01, 2005
Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology (2011) 1.32
Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag (2007) 1.09
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest (2005) 2.60
Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med (2006) 9.17
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
A randomized study of endobronchial valves for advanced emphysema. N Engl J Med (2010) 6.23
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med (2012) 5.37
Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med (2003) 2.94
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med (2007) 2.86
Evaluation of an intensive insulin protocol for septic patients in a medical intensive care unit. Crit Care Med (2006) 2.22
Biologic lung volume reduction in advanced upper lobe emphysema: phase 2 results. Am J Respir Crit Care Med (2009) 1.78
Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol (2009) 1.78
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med (2013) 1.69
alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note. Chest (2008) 1.60
Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest (2003) 1.54
Neurocognitive impairment in obstructive sleep apnea. Chest (2012) 1.50
COPD and lung cancer: are they both airways diseases? Chest (2010) 1.41
Obese man treated with drotrecogin alfa (activated). Ann Pharmacother (2003) 1.38
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum (2007) 1.35
Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann Behav Med (2007) 1.27
Pneumothorax in cystic fibrosis. Chest (2005) 1.25
Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest (2005) 1.22
Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax (2007) 1.12
Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med (2010) 1.09
IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency. Am J Respir Cell Mol Biol (2007) 1.08
Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. Clin Gastroenterol Hepatol (2005) 1.04
Emphysema lung lobe volume reduction: effects on the ipsilateral and contralateral lobes. Eur Radiol (2012) 0.94
Mortality in individuals with severe deficiency of alpha1-antitrypsin: findings from the National Heart, Lung, and Blood Institute Registry. Chest (2005) 0.91
Baseline regional perfusion impacts exercise response to endobronchial valve therapy in advanced pulmonary emphysema. Chest (2013) 0.90
Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest (2008) 0.90
Detection of alpha-1 antitrypsin deficiency by respiratory therapists: experience with an educational program. Respir Care (2013) 0.88
Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. Respir Res (2012) 0.88
A 56-year-old woman with arm pain, dyspnea, and an elevated diaphragm. Chest (2008) 0.87
Chest ultrasound for "Dummies". Chest (2003) 0.86
Circulating polymers in α1-antitrypsin deficiency. Eur Respir J (2014) 0.85
Primary care diagnosis of alpha-1 antitrypsin deficiency: issues and opportunities. Cleve Clin J Med (2007) 0.85
Empiric auto-titrating CPAP in people with suspected obstructive sleep apnea. J Clin Sleep Med (2010) 0.85
Scleroderma lung disease: "if you don't know where you are going, any road will take you there". Am J Respir Crit Care Med (2008) 0.84
Expanded carrier screening panels-does bigger mean better? J Community Genet (2013) 0.83
Barriers to genetic testing among persons at risk for alpha-1 antitrypsin deficiency. Genet Test (2008) 0.83
The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. COPD (2012) 0.82
Asthma and allergy in alpha-1 antitrypsin deficiency. Respir Med (2006) 0.82
The impact of age on outcomes in chronic obstructive pulmonary disease differs by relationship status. J Behav Med (2013) 0.81
Association of cigarette smoking and CRP levels with DNA methylation in α-1 antitrypsin deficiency. Epigenetics (2012) 0.81
Adverse events during the Scleroderma Lung Study. Am J Med (2011) 0.81
Segmental approach to lung volume reduction therapy for emphysema patients. Respiration (2014) 0.80
Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. Respir Med (2012) 0.80
Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med (2016) 0.80
Radiation therapy for palliation of Eisenmenger's syndrome-associated painful splenomegaly. Radiat Med (2008) 0.79
Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. COPD (2006) 0.78
Prospective impact of illness uncertainty on outcomes in chronic lung disease. Health Psychol (2013) 0.78
Effect of obstructive sleep apnea treatment on mail-in cognitive function screening instrument. Am J Med Sci (2014) 0.78
"The lion, the witch and the wardrobe": impact on sibs of individuals with AAT deficiency. Am J Med Genet A (2004) 0.78
Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease? Pulm Med (2010) 0.78
Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. BMC Clin Pharmacol (2010) 0.78
Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother (2015) 0.77
The prospective association of perceived criticism with dyspnea in chronic lung disease. J Psychosom Res (2013) 0.77
Alcohol use predicts ER visits in individuals with alpha-1 antitrypsin deficiency (AATD) associated COPD. COPD (2012) 0.77
Alpha-1 Foundation research registry: from the past to the future. J Pediatr Gastroenterol Nutr (2002) 0.77
Is systemic sclerosis interstitial lung disease slowly progressive? J Bras Pneumol (2011) 0.76
Patterns of Emphysema Heterogeneity. Respiration (2015) 0.76
Opportunities and challenges in the study of pulmonary arterial hypertension. Am J Respir Crit Care Med (2009) 0.75
Unilateral pulmonary artery aplasia in a pregnant patient. Case Rep Med (2011) 0.75
Genetics' influence on patient experiences with a rare chronic disorder: a photovoice study of living with alpha-1 antitrypsin deficiency. Nurs Clin North Am (2013) 0.75
How should we treat vascular and fibrotic lung disease in scleroderma? F1000 Med Rep (2009) 0.75
The social environment and illness uncertainty in chronic obstructive pulmonary disease. Int J Behav Med (2015) 0.75
Differences in adjustment between individuals with alpha-1 antitrypsin deficiency (AATD)-associated COPD and non-AATD COPD. COPD (2013) 0.75
Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment. COPD (2013) 0.75
The Alpha-1 Association Genetic Counseling Program: an innovative approach to service. J Genet Couns (2011) 0.75
Rude awakening: acute abdominal pain with spontaneous resolution. Am J Med (2012) 0.75
Impact of medications on cognitive function in obstructive sleep apnea syndrome. Sleep Breath (2015) 0.75
Multiorgan system dysfunction in the chylomicronemia syndrome. J Intensive Care Med (2013) 0.75